XML 53 R34.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Year ended December 31, 2018
|  | US |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 4,807 |  |  | $ | 207 |  |  | $ | 5,014 |
Neulasta® (pegfilgrastim) |  | 3,866 |  |  | 609 |  |  | 4,475 |
Prolia® (denosumab) |  | 1,500 |  |  | 791 |  |  | 2,291 |
Aranesp® (darbepoetin alfa) |  | 942 |  |  | 935 |  |  | 1,877 |
XGEVA® (denosumab) |  | 1,338 |  |  | 448 |  |  | 1,786 |
Sensipar® / Mimpara® (cinacalcet) |  | 1,436 |  |  | 338 |  |  | 1,774 |
EPOGEN® (epoetin alfa) |  | 1,010 |  |  | — |  |  | 1,010 |
Other products |  | 2,530 |  |  | 1,776 |  |  | 4,306 |
Total product sales(1) |  | 17,429 |  |  | 5,104 |  |  | 22,533 |
Other revenues |  | 929 |  |  | 285 |  |  | 1,214 |
Total revenues(2) |  | $ | 18,358 |  |  | $ | 5,389 |  |  | $ | 23,747 |
|  | Year ended December 31, 2017
|  | US |  | ROW |  | Total
ENBREL |  | $ | 5,206 |  |  | $ | 227 |  |  | $ | 5,433 |
Neulasta® |  | 3,931 |  |  | 603 |  |  | 4,534 |
Aranesp® |  | 1,114 |  |  | 939 |  |  | 2,053 |
Prolia® |  | 1,272 |  |  | 696 |  |  | 1,968 |
Sensipar® / Mimpara® |  | 1,374 |  |  | 344 |  |  | 1,718 |
XGEVA® |  | 1,157 |  |  | 418 |  |  | 1,575 |
EPOGEN® |  | 1,096 |  |  | — |  |  | 1,096 |
Other products |  | 1,981 |  |  | 1,437 |  |  | 3,418 |
Total product sales(1) |  | 17,131 |  |  | 4,664 |  |  | 21,795 |
Other revenues |  | 898 |  |  | 156 |  |  | 1,054 |
Total revenues(2) |  | $ | 18,029 |  |  | $ | 4,820 |  |  | $ | 22,849 |
|  | Year ended December 31, 2016
|  | US |  | ROW |  | Total
ENBREL |  | $ | 5,719 |  |  | $ | 246 |  |  | $ | 5,965 |
Neulasta® |  | 3,925 |  |  | 723 |  |  | 4,648 |
Aranesp® |  | 1,082 |  |  | 1,011 |  |  | 2,093 |
Prolia® |  | 1,049 |  |  | 586 |  |  | 1,635 |
Sensipar® / Mimpara® |  | 1,240 |  |  | 342 |  |  | 1,582 |
XGEVA® |  | 1,115 |  |  | 414 |  |  | 1,529 |
EPOGEN® |  | 1,282 |  |  | — |  |  | 1,282 |
Other products |  | 1,913 |  |  | 1,245 |  |  | 3,158 |
Total product sales(1) |  | 17,325 |  |  | 4,567 |  |  | 21,892 |
Other revenues |  | 1,001 |  |  | 98 |  |  | 1,099 |
Total revenues(2) |  | $ | 18,326 |  |  | $ | 4,665 |  |  | $ | 22,991 |
____________
(1) | Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2018 and 2017. For the year ended December 31, 2016, hedging gains were $308 million.
(2) | Prior-period amounts are not adjusted under the modified-retrospective method of adoption of the new revenue recognition accounting standard.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration